1. Home
  2. EOLS vs SHBI Comparison

EOLS vs SHBI Comparison

Compare EOLS & SHBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EOLS
  • SHBI
  • Stock Information
  • Founded
  • EOLS 2012
  • SHBI 1876
  • Country
  • EOLS United States
  • SHBI United States
  • Employees
  • EOLS N/A
  • SHBI N/A
  • Industry
  • EOLS Biotechnology: Pharmaceutical Preparations
  • SHBI Major Banks
  • Sector
  • EOLS Health Care
  • SHBI Finance
  • Exchange
  • EOLS Nasdaq
  • SHBI Nasdaq
  • Market Cap
  • EOLS 589.3M
  • SHBI 548.7M
  • IPO Year
  • EOLS 2018
  • SHBI N/A
  • Fundamental
  • Price
  • EOLS $9.53
  • SHBI $15.83
  • Analyst Decision
  • EOLS Strong Buy
  • SHBI Buy
  • Analyst Count
  • EOLS 5
  • SHBI 2
  • Target Price
  • EOLS $23.75
  • SHBI $20.00
  • AVG Volume (30 Days)
  • EOLS 889.3K
  • SHBI 193.2K
  • Earning Date
  • EOLS 08-05-2025
  • SHBI 07-24-2025
  • Dividend Yield
  • EOLS N/A
  • SHBI 3.03%
  • EPS Growth
  • EOLS N/A
  • SHBI 169.44
  • EPS
  • EOLS N/A
  • SHBI 1.61
  • Revenue
  • EOLS $275,463,000.00
  • SHBI $208,209,000.00
  • Revenue This Year
  • EOLS $33.42
  • SHBI N/A
  • Revenue Next Year
  • EOLS $33.18
  • SHBI $7.22
  • P/E Ratio
  • EOLS N/A
  • SHBI $9.82
  • Revenue Growth
  • EOLS 25.38
  • SHBI 24.24
  • 52 Week Low
  • EOLS $8.67
  • SHBI $11.47
  • 52 Week High
  • EOLS $17.82
  • SHBI $17.61
  • Technical
  • Relative Strength Index (RSI)
  • EOLS 51.00
  • SHBI 46.08
  • Support Level
  • EOLS $9.12
  • SHBI $16.42
  • Resistance Level
  • EOLS $10.20
  • SHBI $16.84
  • Average True Range (ATR)
  • EOLS 0.40
  • SHBI 0.38
  • MACD
  • EOLS 0.05
  • SHBI -0.13
  • Stochastic Oscillator
  • EOLS 44.17
  • SHBI 16.97

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

About SHBI Shore Bancshares Inc

Shore Bancshares Inc is a financial holding company. It offers personalized banking, insurance, and investment services to families and businesses in the Mid-Atlantic region. It operates in one business segment- banking. The company's primary source of revenue is derived from interest earned on commercial, residential mortgage and other loans, and fees charged in connection with lending and other banking services located in Maryland, Delaware and Virginia.

Share on Social Networks: